The abrogation of the ATR/CHK1 replication stress response checkpoint in the absence of FACT suggests that FACT inhibition could be used to target DNA replication in cells with preexisting high levels of replication stress (e.g., cancer cells) with minimal effects on cells with low levels of replication stress (i.e., normal cells). The gene discussed is SUPT16H; the disease is cancer.